Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Srivani Srikantiah

Internal Medicine Scottsdale, AZ Medical Doctor

NPI 1255467270 CMS profile 192804

8901 E Raintree Dr Ste 150, Scottsdale, AZ 85260

Open in the dashboard

General payments

$6,732

347 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Srivani Srikantiah of Scottsdale, AZ is reported in the CMS Open Payments database as having received $6,732 across 347 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $238 4
2024 General $761 30
2023 General $1,255 62
2022 General $1,270 57
2021 General $1,157 63
2020 General $554 31
2019 General $1,496 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Srivani Srikantiah
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Srivani Srikantiah were reported at $238. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Srivani Srikantiah Internal Medicine median Middle half National median
2019 $1,496 $159 $48–$570 $163
2020 $554 $119 $33–$402 $114
2021 $1,157 $135 $37–$521 $132
2022 $1,270 $141 $42–$496 $149
2023 $1,255 $149 $45–$519 $160
2024 $761 $154 $47–$537 $164
2025 $238 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $927 70 payments
  2. AstraZeneca Pharmaceuticals LP $806 29 payments
  3. AbbVie, Inc. $565 29 payments
  4. Amgen Inc. $413 23 payments
  5. Lilly USA, LLC $397 16 payments
  6. Boston Scientific Corporation $271 6 payments
  7. Sanofi-Aventis U.S. LLC $269 20 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $268 11 payments
  9. Abbott Laboratories $251 11 payments
  10. Lucid Diagnostics Inc. $213 7 payments
  11. Other $2,351 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,707 345 payments
  2. Entertainment $19 1 payment
  3. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $602 22 payments
  2. UBRELVY $329 18 payments
  3. EVENITY $284 16 payments
  4. Prolia $284 16 payments
  5. Ozempic $279 21 payments
  6. Kerendia $268 11 payments
  7. BREZTRI $223 3 payments
  8. ZENPEP $200 11 payments
  9. RYBELSUS $195 10 payments
  10. Tresiba $195 24 payments
  11. Other $4,607 237 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,173

Median for Internal Medicine: 777

Drug cost

$60,977

Median for Internal Medicine: $73,373

Branded share of claims

9.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 30 $32,844
Farxiga Dapagliflozin Propanediol Brand 12 $15,731
Levothyroxine Sodium Generic 108 $1,198
Ibandronate Sodium Generic 15 $1,194
Rosuvastatin Calcium Generic 95 $991
Atorvastatin Calcium Generic 77 $790
Losartan Potassium Generic 91 $713
Montelukast Sodium Generic 32 $697
Simvastatin Generic 51 $589
Sertraline Hcl Generic 95 $577

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$57,953

Medicare's payments for the services billed

Medicare patients

147

Average age 76

Services billed

689

102 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 56%
Ischemic heart disease 29%
Diabetes 27%
Cancer 20%
Osteoporosis 20%
Depression 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $153
$153 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $69
$69 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $67
$67 — —
Auvelity
  • Axsome Therapeutics, Inc. $53
$53 — —
CONTRAVE
  • Currax Pharmaceuticals LLC $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

347 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record